Literature DB >> 2348835

Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients.

P Ahonen1, S Myllärniemi, I Sipilä, J Perheentupa.   

Abstract

To define the clinical picture and course of the autosomal recessive disease called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), we report data from our 10-month to 31-year follow-up of 68 patients from 54 families, now 10 months to 53 years of age. The clinical manifestations varied greatly and included from one to eight disease components, 63 percent of the patients having three to five of them. The initial manifestation was oral candidiasis in 41 patients (60 percent), intestinal malabsorption in 6 (9 percent), and keratopathy in 2 (3 percent). All the patients had candidiasis at some time. The earliest endocrine component appeared at 19 months to 35 years of age. Hypoparathyroidism was present in 54 patients (79 percent), adrenocortical failure in 49 (72 percent), and gonadal failure in 15 (60 percent) of the female patients greater than or equal to 13 years of age and 4 (14 percent) of the male patients greater than or equal to 16 years of age. There were multiple endocrine deficiencies in half the patients. From 4 to 29 percent of the patients had periodic malabsorption, gastric parietal-cell atrophy, hepatitis, alopecia, vitiligo, or a combination of these conditions. Dental-enamel hypoplasia and keratopathy were also frequent but were not attributable to hypoparathyroidism. In the patients whose initial manifestation (other than candidiasis) was adrenal failure, the other components developed less often than in the remaining patients. We conclude that the clinical spectrum in patients with APECED is broad. The majority of patients have three to five manifestations, some of which may not appear until the fifth decade. Therefore, all patients need lifelong follow-up for the detection of new components of the disease.

Entities:  

Mesh:

Year:  1990        PMID: 2348835     DOI: 10.1056/NEJM199006283222601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  191 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Autoimmune polyglandular syndrome type 1.

Authors:  P Obermayer-Straub; C P Strassburg; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 3.  Autoimmunity in liver diseases.

Authors:  C P Strassburg; P Obermayer-Straub; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 4.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 5.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

Review 6.  Fungal skin infections.

Authors:  R J Hay
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

Review 7.  Genetic susceptibility in type 1 diabetes and its associated autoimmune disorders.

Authors:  Akane Ide; George S Eisenbarth
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 8.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity.

Authors:  P Peterson; J Pitkänen; N Sillanpää; K Krohn
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 9.  Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders.

Authors:  Ramona Goyal; Ariel C Bulua; Nikolay P Nikolov; Pamela L Schwartzberg; Richard M Siegel
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

10.  Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB.

Authors:  C Ding; B Buckingham; M A Levine
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.